{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:50:49Z","timestamp":1791247849861,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMFTR Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhepr.2026.101943","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:43:17Z","timestamp":1782862997000},"page":"101943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-3316","authenticated-orcid":false,"given":"Thomas","family":"Michler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6352-1415","authenticated-orcid":false,"given":"Anna","family":"Kosinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-6073","authenticated-orcid":false,"given":"Osman","family":"Merdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-7008","authenticated-orcid":false,"given":"Till","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edanur Ates","family":"\u00d6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk H.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101943_bib1","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"key":"10.1016\/j.jhepr.2026.101943_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/d41586-018-07592-7","article-title":"The silent epidemic killing more people than HIV, malaria or TB","volume":"564","author":"Graber-Stiehl","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101943_bib3","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101943_bib4","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101943_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib6","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA \u2013 the holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib8","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101943_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/vaccines9080841","article-title":"Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection","volume":"9","author":"Kosinska","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhepr.2026.101943_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105896","article-title":"The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice","volume":"226","author":"Michler","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2026.101943_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib12","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101943_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01127-25","article-title":"Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models","volume":"70","author":"Noack","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhepr.2026.101943_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106321","article-title":"Update on combination therapies against HBV in clinical investigations","volume":"245","author":"Mak","year":"2026","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2026.101943_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.gt.3302449","article-title":"Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice","volume":"12","author":"Dumortier","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhepr.2026.101943_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2026.101943_bib21","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jhepr.2026.101943_bib22","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201506172","article-title":"Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA","author":"Michler","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2015.12.060","article-title":"Protein-prime\/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice","volume":"34","author":"Backes","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jhepr.2026.101943_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhepr.2026.101943_bib25","article-title":"HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx","volume":"6","author":"Ringelhan","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101943_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/liv.13884","article-title":"Liver macrophages: friend or foe during hepatitis B infection?","volume":"38","author":"Faure-Dupuy","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101943_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20121172","article-title":"Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion","volume":"210","author":"Peppa","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib29","article-title":"Hepatitis B virus \u2013 specific and global T-cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101943_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40259-024-00694-x","article-title":"Investigational RNA interference agents for hepatitis B","volume":"39","author":"Hui","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.jhepr.2026.101943_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: reef-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.jhepr.2026.101943_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jviromet.2007.01.027","article-title":"Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies","volume":"142","author":"van der Laan","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jhepr.2026.101943_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101943_bib35","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101943_bib36","article-title":"Innate immune recognition in hepatitis B virus infection","volume":"16","author":"Li","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.jhepr.2026.101943_bib37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101943_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.30054","article-title":"Hepatitis B virus evasion from cyclic guanosine monophosphate-adenosine monophosphate synthase sensing in human hepatocytes","volume":"68","author":"Verrier","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101943_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/cmi.2010.36","article-title":"Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex","volume":"7","author":"Wang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhepr.2026.101943_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005693","article-title":"Hepatitis B virus-induced parkin-dependent recruitment of linear ubiquitin assembly complex (LUBAC) to mitochondria and attenuation of innate immunity","volume":"12","author":"Khan","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhepr.2026.101943_bib41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s13238-010-0141-8","article-title":"Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein","volume":"1","author":"Jiang","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.jhepr.2026.101943_bib42","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/JVI.02760-14","article-title":"Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2026.101943_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000986","article-title":"Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion","volume":"6","author":"Wang","year":"2010","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhepr.2026.101943_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/liv.12244","article-title":"miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes","volume":"34","author":"Hou","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101943_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41467-020-20316-8","article-title":"Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101943_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12985-022-01785-3","article-title":"HBx inhibits DNA sensing signaling pathway via ubiquitination and autophagy of cGAS","volume":"19","author":"Chen","year":"2022","journal-title":"Virol J"},{"key":"10.1016\/j.jhepr.2026.101943_bib47","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2012.05.003","article-title":"Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection","volume":"11","author":"Wang","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhepr.2026.101943_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.101943_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv3678","article-title":"Targeting HBV with RNA interference: paths to cure","volume":"17","author":"Iannacone","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2026.101943_bib51","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib52","first-page":"314","article-title":"Reduction in Intrahepatic cccDNA and Integration of HBV in chronic hepatitis B patients with a functional cure","volume":"11","author":"Gan","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhepr.2026.101943_bib53","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:52:26Z","timestamp":1791244346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589555926002144"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101943","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101943"}}